查看購物車
  • Simplified Chinese
  • English
  • Japanese
  • Korean
人類疫苗佐劑市場規模和預測、全球和區域佔有率、趨勢和成長機會分析報告範圍：按類型、應用（流感、肝炎、人類乳頭狀瘤病毒等）、最終用戶和地理位置
市場調查報告書
商品編碼
1424141

人類疫苗佐劑市場規模和預測、全球和區域佔有率、趨勢和成長機會分析報告範圍：按類型、應用（流感、肝炎、人類乳頭狀瘤病毒等）、最終用戶和地理位置

Human Vaccine Adjuvants Market Size and Forecast, Global and Regional Share, Trends, and Growth Opportunity Analysis Report Coverage: By Type, Application (Influenza, Hepatitis, Human papilloma virus, and Others), End User, and Geography
出版日期: | 出版商: The Insight Partners | 英文 199 Pages | 訂單完成後即時交付

價格

全球人用疫苗佐劑市場預計將從2022年的15.71億美元增至2030年的44.89億美元。預計2022年至2030年該市場將以14.0%的CAGR成長。推動人用疫苗佐劑市場成長的關鍵因素包括慢性病盛行率上升以及對免疫計劃的日益關注。

人用疫苗佐劑市場的市場機會

不斷擴大的製藥業預計將對佐劑的需求產生積極影響，因為它們可以提高疫苗的功效和安全性。製藥業日益關注傳染病、癌症和自體免疫疾病，為開發針對這些特定疾病領域的個人化疫苗和佐劑提供了平台。這為佐劑製造商提供了開發專門佐劑以增強對這些疾病疫苗的免疫反應的機會。

美國擁有全球研發最密集的製藥業之一。根據歐洲製藥工業協會聯合會（EFPIA）的數據，北美市場（美國和加拿大）仍然是全球最大市場，佔有率為 49.1%，遠遠領先歐洲、中國和日本。美國是創新研發投資的全球領導者，在過去十年中，該國生產了全球一半以上的新分子。此外，根據 EFPIA 的數據，2021 年，北美佔全球藥品銷售額的 49.1%，而歐洲為 23.4%。

同樣，根據 EFPIA 的數據，與歐盟前五市場和美國市場相比，巴西、中國和印度製藥業在 2016-2021 年期間分別成長了 11.7%、6.7% 和 11.8%，平均市場成長率分別為5.8 %和5.6%。此外，根據印度品牌資產基金會 (IBEF) 的數據，印度是全球製藥業的一個主要且正在崛起的參與者。該國是世界上最大的學名藥貿易國，佔全球供應量的近20%。它供應了全球約 50% 的疫苗接種需求。國內製藥業包括 3,000 家製藥公司和約 10,500 個製造單位。根據印度政府的官方數據，印度醫藥產業價值近500億美元，其中超過250億美元來自出口。印度佔世界學名藥出口的 20% 左右。此外，日本是世界上最大的藥品市場之一。根據日本厚生勞動省（MHLW）年度藥品生產統計數據，2020 年日本處方藥和非處方藥市場規模為 1,070 億美元。

隨著產業的不斷發展和創新，對能夠支持個人化疫苗開發的佐劑的需求不斷增加，推動人類疫苗佐劑市場的顯著成長和投資。因此，全球不斷成長的製藥業可能會在未來幾年為人類疫苗佐劑市場創造利潤豐厚的成長機會。

阻礙人類疫苗佐劑市場的因素

人用疫苗佐劑的製造是一個複雜的過程，涉及嚴格的監管要求和品質控制措施。佐劑的生產需要專門的設備和設施，並嚴格遵守良好生產規範（GMP）和其他監管標準，以確保最終產品的純度、安全性和功效。由於滿足這些要求的資源和專業知識有限，這可能會給製造商，特別是小型公司或新進入者帶來重大挑戰。

監管挑戰也在限制人用疫苗佐劑市場方面發揮重要作用。佐劑被認為是疫苗的關鍵組成部分，受到歐洲藥品管理局（EMA）和美國食品藥物管理局（FDA）等衛生當局的嚴格監管。佐劑的法規核准過程可能漫長而複雜，需要大量的臨床前和臨床資料來證明安全性、有效性和品質。它可能對製造商構成重大障礙，因為獲得監管部門批准所需的成本和時間可能相當大。因此，上述因素阻礙了人用疫苗佐劑市場的成長。

人用疫苗佐劑市場：細分概述

依類型，人用疫苗佐劑市場分為顆粒佐劑、乳液佐劑、組合佐劑等。顆粒佐劑細分市場將在 2022 年佔據更大的市場佔有率。然而，乳液佐劑細分市場預計從 2022 年至 2030 年將在市場上實現更高的CAGR。顆粒佐劑由顆粒組成，通常為奈米或微米尺寸，旨在模仿病原體或細胞結構，刺激強大的免疫反應。這些佐劑增強免疫細胞對抗原的攝取並促進免疫活化。顆粒佐劑的著名例子包括鋁鹽（明礬），幾十年來一直用於人類疫苗中以增強抗體反應，以及新開發的產品，例如病毒樣顆粒（VLP）和基於奈米顆粒的佐劑。

依應用，人用疫苗佐劑市場分為流感、肝炎、人類乳突病毒（HPV）等。流感細分市場在 2022 年佔據最大市場佔有率，預計 2022 年至 2030 年市場複合CAGR最高。流感疫苗對於預防季節性流感爆發和潛在大流行至關重要。它們針對的是一種快速進化的病毒，需要不斷更新疫苗以匹配流行的病毒株。流感疫苗中使用的佐劑可增強免疫反應，特別是在老年人或免疫功能低下的個體等高風險族群。它們也支持廣泛保護性、交叉反應性免疫反應的發展。

就最終用戶而言，人用疫苗佐劑市場分為製藥和生技公司、CMO 和 CRO 等。製藥和生物技術公司細分市場在 2022 年佔據最大佔有率，預計 2022 年至 2030 年CAGR最高。製藥和生物技術公司在疫苗的研究、開發和商業化中發揮核心作用，包括針對多種傳染病和健康狀況的佐劑疫苗製劑。這些公司處於疫苗創新的前沿，在臨床前和臨床開發階段推動佐劑技術、候選疫苗和佐劑疫苗配方的發現和最佳化。

人類疫苗佐劑市場：地理概況

2022年，北美佔據全球最大的人用疫苗佐劑市場。美國在北美人用疫苗佐劑市場中佔有重要佔有率。該國的市場成長主要歸因於政府醫療保健支出的增加以及對新型疫苗配方的需求激增，以更有效地治療傳染病。根據美國醫療保險和醫療補助服務中心的數據，2021 年美國國民醫療保健支出成長 2.7%，達到 4.3 兆美元，即人均 12,914 美元。醫療衛生支出佔全國GDP的18.3%。美國衛生與公眾服務部預計，2019-2028年國家衛生支出將以年均5.4%的速度成長，到2028年將達到6.2兆美元。衛生支出的上升可能導致資金配置增加用於疫苗的研發，刺激了對人用疫苗佐劑的需求。

根據 2020 年 7 月發布的全球疾病負擔研究的新發現，美國的非傳染性疾病和傳染病負擔巨大且不斷增加。據約翰霍普金斯大學稱，近二十年來，美國SARS、萊姆病、登革熱、西尼羅河病毒、寨卡病毒等疾病感染病例迅速增加。此外，同一消息來源也證實，瘧疾、結核病、霍亂、百日咳、流感、肺炎球菌疾病和淋病等重新出現的疾病的發生率增加。同樣，根據美國疾病管制與預防中心 (CDC) 的數據，2010 年至 2022 年間，流感每年導致 100,000 至 710,000 人住院治療，4,900 至 52,000 人死亡。根據 ICO/IARC 資訊中心 2023 年 HPV 和癌症報告有1.405 億15 歲及以上女性面臨HPV 相關子宮頸癌的風險。在美國普通人群中，預計有近 3.9% 的女性在特定時間攜帶子宮頸 HPV16/18 感染，71.2% 的浸潤性子宮頸癌歸因於 HPV 16 或 18。感染和重新出現的疾病推動了公司在疫苗開發方面的努力，推動了美國人類疫苗佐劑市場的成長。

美國政府努力為國內藥品和保健產品的開發和商業化創造有利的環境。該國擁有多個潛在的製藥和醫療器材市場參與者，包括輝瑞、諾華、波士頓科學、Integra LifeSciences、安進和雅培，其製藥和醫療器材行業創新擁有各種專利。因此，各製藥巨頭藥物開發活動的增加提振了美國的人用疫苗佐劑市場。

在準備人類疫苗佐劑市場報告時提到的一些主要一手和二手來源包括世界銀行數據、國家衛生服務體系 (NHS)、FDA（食品和藥物管理局）、EMA（歐洲藥品管理局）和WHO（世界衛生組織）。

目錄

第 1 章：簡介

第 2 章：執行摘要

  • 重要見解

第 3 章：研究方法

  • 覆蓋範圍
  • 二次研究
  • 初步研究

第 4 章：人用疫苗佐劑市場格局

  • 概述
  • PEST分析

第 5 章：人類疫苗佐劑市場 - 主要市場動態

  • 人類疫苗佐劑市場 - 主要市場動態
  • 市場促進因素
    • 慢性病盛行率上升
    • 越來越關注免疫計劃
  • 市場限制
    • 製造複雜性和監管挑戰
  • 市場機會
    • 不斷發展的製藥業
  • 未來的趨勢
    • 個人化疫苗的上升趨勢
  • 促進因素和限制的影響：

第 6 章：人類疫苗佐劑市場 - 全球市場分析

  • 人類疫苗佐劑市場收入，2022 - 2030
  • 人用疫苗佐劑市場預測分析

第 7 章：人類疫苗佐劑市場分析 - 按類型

  • 顆粒佐劑
  • 乳化助劑
  • 組合佐劑
  • 其他

第 8 章：人類疫苗佐劑市場分析 -按應用

  • 流感
  • 肝炎
  • 人類乳突病毒（HPV）
  • 其他

第 9 章：人類疫苗佐劑市場分析 - 按最終用戶

  • 製藥和生物技術公司
  • CMO 和 CRO
  • 其他

第 10 章：人類疫苗佐劑市場 - 地理分析

  • 北美洲
    • 美國
    • 加拿大
    • 墨西哥
  • 歐洲
    • 德國
    • 英國
    • 法國
    • 義大利
    • 西班牙
    • 歐洲其他地區
  • 亞太地區
    • 中國
    • 日本
    • 印度
    • 澳洲
    • 韓國
    • 亞太地區其他地區
  • 中東和非洲
    • 沙烏地阿拉伯
    • 南非
    • 阿拉伯聯合大公國
    • 中東和非洲其他地區
  • 南美洲和中美洲
    • 巴西
    • 阿根廷
    • 南美洲和中美洲其他地區

第 11 章：產業格局

  • 概述

第 12 章：公司簡介

  • Novartis AG
  • Dynavax Technologies Corp
  • CSL Ltd
  • Seppic SA
  • SPI Pharma Inc
  • Hawaii Biotech Inc
  • Croda International Plc
  • Novavax Inc
  • Phibro Animal Health Corp
  • Creative Biolabs Inc

第 13 章：附錄

Product Code: TIPRE00020517

The global human vaccine adjuvants market is expected to reach US$ 4.489 billion in 2030 from US$ 1.571 billion in 2022. The market is estimated to grow with a CAGR of 14.0% from 2022 to 2030. Key factors driving the human vaccine adjuvants market growth include the rising prevalence of chronic diseases and growing focus on immunization programs.

Market Opportunities of Human Vaccine Adjuvants Market

The expanding pharmaceutical industry is expected to positively influence the demand for adjuvants as they can improve the efficacy and safety of vaccines. The pharmaceutical industry's increasing focus on infectious diseases, cancer, and autoimmune disorders provides a platform for developing personalized vaccines and adjuvants targeted at these specific disease areas. This offers an opportunity for adjuvant manufacturers to develop specialized adjuvants to enhance the immune response to vaccines for these diseases.

The US has one of the most R&D-intensive pharmaceutical industries globally. According to the European Federation of Pharmaceutical Industries and Associations (EFPIA), the North America market (US and Canada) remained the world's largest market with a 49.1% share, well ahead of Europe, China, and Japan. The US is the global leader in innovative R&D investments, and the country produced over half of the world's new molecules in the last decade. Additionally, as per EFPIA, in 2021, North America accounted for 49.1% of global pharmaceutical sales, compared with 23.4% for Europe.

Similarly, according to the EFPIA, the Brazilian, Chinese, and Indian pharmaceutical industries grew by 11.7%, 6.7%, and 11.8% during the 2016-2021 period, respectively, compared to the top five European Union markets and the US market, which recorded an average market growth of 5.8% and 5.6%, respectively. Furthermore, as per the India Brand Equity Foundation (IBEF), India is a major and rising global pharmaceutical industry player. The country is the world's largest trader of generic medications, accounting for nearly 20% of the worldwide supply by volume. It supplies ~50% of the global vaccination demand. The domestic pharmaceutical industry includes a network of 3,000 drug companies and ~10,500 manufacturing units. Based on official figures from the Indian government, the pharmaceutical sector in India is valued at nearly US$ 50 billion, of which over US$ 25 billion is derived from exports. India accounts for ~20% of the world's generic medicine exports. Further, Japan is one of the largest pharmaceutical markets in the world. According to the Ministry of Health, Labor and Welfare's (MHLW) Annual Pharmaceutical Production Statistics, the Japanese market for prescription and nonprescription pharmaceuticals in 2020 was US$ 107 billion.

As the industry continues to evolve and innovate, there is an increasing demand for adjuvants that can support the development of personalized vaccines, driving significant growth and investment in the human vaccine adjuvants market. Thus, the growing pharmaceutical industry worldwide will likely create lucrative growth opportunities for the human vaccine adjuvants market in the coming years.

Factors Hampering Human Vaccine Adjuvants Market

Manufacturing human vaccine adjuvant is a complex process involving stringent regulatory requirements and quality control measures. The production of adjuvants requires specialized equipment and facilities with strict adherence to Good Manufacturing Practices (GMP) and other regulatory standards to ensure the final product's purity, safety, and efficacy. This can pose significant challenges for manufacturers, especially smaller companies or new entrants, owing to limited resources and expertise to meet these requirements.

Regulatory challenges also play a significant role in restraining the human vaccine adjuvants market. Adjuvants are considered critical components of vaccines, and they are subjected to strict regulatory oversight by health authorities such as the European Medicines Agency (EMA) in Europe and the Food and Drug Administration (FDA) in the US. The regulatory approval process for adjuvants can be lengthy and complex, requiring extensive preclinical and clinical data to demonstrate safety, efficacy, and quality. It can pose a significant barrier for manufacturers, as the cost and time required to obtain regulatory approval can be substantial. Thus, the factors mentioned above hamper the growth of the human vaccine adjuvants market.

Human Vaccine Adjuvants Market: Segmental Overview

Based on type, the human vaccine adjuvants market is segmented into particulate adjuvants, emulsion adjuvants, combination adjuvants, and others. The particulate adjuvant segment held a larger share of the market in 2022. However, the emulsion adjuvants segment is expected to register a higher CAGR in the market from 2022 to 2030. Particulate adjuvants consist of particles, often of nanometer or micrometer size, designed to mimic pathogens or cellular structures, stimulating a robust immune response. These adjuvants enhance antigen uptake by immune cells and promote immune activation. Notable examples of particulate adjuvants include aluminum salts (Alum), which have been used for decades in human vaccines to enhance antibody responses, and newer developments such as virus-like particles (VLPs) and nanoparticle-based adjuvants.

By application, the human vaccine adjuvants market is segmented into influenza, hepatitis, human papillomavirus (HPV), and others. The influenza segment held the largest share of the market in 2022 and is expected to register the highest CAGR in the market from 2022 to 2030. Influenza vaccines are crucial for preventing seasonal flu outbreaks and potential pandemics. They target a rapidly evolving virus, requiring continual vaccine updating to match circulating strains. Adjuvants used in influenza vaccines enhance immune responses, particularly in high-risk populations such as the elderly or immunocompromised individuals. They also support the development of broadly protective, cross-reactive immune responses.

In terms of end user, the human vaccine adjuvants market is segmented into pharmaceutical and biotechnology companies, CMOs and CROs, and others. The pharmaceutical and biotechnology companies segment held the largest share of the market in 2022 and is expected to register the highest CAGR in the market from 2022 to 2030. Pharmaceutical and biotechnology companies play a central role in the research, development, and commercialization of vaccines, including adjuvanted vaccine formulations, targeting diverse infectious diseases and health conditions. These companies are at the forefront of vaccine innovation, driving the discovery and optimization of adjuvant technologies, vaccine candidates, and adjuvanted vaccine formulations through preclinical and clinical development stages.

Human Vaccine Adjuvants Market: Geographical Overview

North America accounted for the largest global human vaccine adjuvants market share in 2022. The US holds a significant share of North America's human vaccine adjuvants market. The market growth in this country is mainly ascribed to rising government spending on healthcare and a surging demand for novel vaccine formulations to treat infectious diseases more efficiently. According to the US Centers for Medicare & Medicaid Services, national healthcare expenditures in the US increased by 2.7% in 2021, reaching US$ 4.3 trillion or US$ 12,914 per person. Health spending accounted for 18.3% of the nation's GDP. As per the US Department of Health & Human Services, national health spending is expected to grow at an annual rate of 5.4% from 2019-2028, reaching US$ 6.2 trillion by 2028. The rising health expenditure may lead to a rise in funds allocation for the research and development of vaccines, fueling the demand for human vaccine adjuvants.

According to new findings derived from the Global Burden of Disease study published in July 2020, there is a large and increasing burden of noncommunicable and infectious diseases in the US. According to Johns Hopkins University, the cases of diseases such as SARS, Lyme disease, dengue fever, West Nile virus, and Zika virus infection have increased rapidly in the last two decades in the US. Also, the same source affirmed an increase in the incidence of re-emerging diseases such as malaria, tuberculosis, cholera, pertussis, influenza, pneumococcal disease, and gonorrhea. Similarly, according to the Centers for Disease Control and Prevention (CDC), flu has resulted in 100,000 to 710,000 hospitalizations and 4,900 to 52,000 deaths annually between 2010 and 2022. According to a report by ICO/IARC Information Centre on HPV and Cancer in 2023, the US has a population of 140.5 million women aged 15 years and older who are at risk of developing HPV-related cervical cancer. Nearly 3.9% of women in the US in the general population are projected to harbor cervical HPV16/18 infection at a given time, and 71.2% of invasive cervical cancers are attributed to HPVs 16 or 18. Thus, a rise in the incidences of various infections and re-emerging diseases boosts companies' efforts in vaccine development, fueling the human vaccine adjuvants market growth in the US.

The US government strives to create a conducive environment for developing and commercializing pharmaceutical and healthcare products in the country. The country has several potential pharmaceutical and medical device market players, including Pfizer, Novartis, Boston Scientific, Integra LifeSciences, Amgen, and Abbott, with various patents for their pharmaceutical and medical device industry innovations. Thus, an increase in drug development activities by various pharmaceutical giants bolsters the human vaccine adjuvants market in the US.

A few of the major primary and secondary sources referred to while preparing the report on the human vaccine adjuvants market are the World Bank Data, National Health Service (NHS), FDA (Food and Drug Administration), EMA (European Medicines Agency), and WHO (World Health Organization).

Reasons to Buy:

  • Save and reduce time carrying out entry-level research by identifying the growth, size, leading players, and segments in the human vaccine adjuvants market.
  • Highlights key business priorities in order to assist companies to realign their business strategies.
  • The key findings and recommendations highlight crucial progressive industry trends in the global human vaccine adjuvants market, thereby allowing players across the value chain to develop effective long-term strategies.  
  • Develop/modify business expansion plans by using substantial growth offering developed and emerging markets.
  • Scrutinize in-depth global market trends and outlook coupled with the factors driving the human vaccine adjuvants market, as well as those hindering it.
  • Enhance the decision-making process by understanding the strategies that underpin security interest with respect to client products, segmentation, pricing, and distribution.

Table Of Contents

1. Introduction

  • 1.1 The Insight Partners Research Report Guidance
  • 1.2 Market Segmentation

2. Executive Summary

  • 2.1 Key Insights

3. Research Methodology

  • 3.1 Coverage
  • 3.2 Secondary Research
  • 3.3 Primary Research

4. Human Vaccine Adjuvants Market Landscape

  • 4.1 Overview
  • 4.2 PEST Analysis

5. Human Vaccine Adjuvants Market - Key Market Dynamics

  • 5.1 Human Vaccine Adjuvants Market - Key Market Dynamics
  • 5.2 Market Drivers
    • 5.2.1 Rising Prevalence of Chronic Diseases
    • 5.2.2 Growing Focus on Immunization Programs
  • 5.3 Market Restraints
    • 5.3.1 Manufacturing Complexities and Regulatory Challenges
  • 5.4 Market Opportunities
    • 5.4.1 Growing Pharmaceutical Industry
  • 5.5 Future Trends
    • 5.5.1 Rising Trend of Personalized Vaccines
  • 5.6 Impact of Drivers and Restraints:

6. Human Vaccine Adjuvants Market - Global Market Analysis

  • 6.1 Human Vaccine Adjuvants Market Revenue (US$ Million), 2022 - 2030
  • 6.2 Human Vaccine Adjuvants Market Forecast Analysis

7. Human Vaccine Adjuvants Market Analysis - by Type

  • 7.1 Particulate Adjuvant
    • 7.1.1 Overview
    • 7.1.2 Particulate Adjuvant: Human Vaccine Adjuvants Market - Revenue and Forecast to 2030 (US$ Million)
  • 7.2 Emulsion Adjuvant
    • 7.2.1 Overview
    • 7.2.2 Emulsion Adjuvant: Human Vaccine Adjuvants Market - Revenue and Forecast to 2030 (US$ Million)
  • 7.3 Combination Adjuvant
    • 7.3.1 Overview
    • 7.3.2 Combination Adjuvant: Human Vaccine Adjuvants Market - Revenue and Forecast to 2030 (US$ Million)
  • 7.4 Others
    • 7.4.1 Overview
    • 7.4.2 Others: Human Vaccine Adjuvants Market - Revenue and Forecast to 2030 (US$ Million)

8. Human Vaccine Adjuvants Market Analysis - by Application

  • 8.1 Influenza
    • 8.1.1 Overview
    • 8.1.2 Influenza: Human Vaccine Adjuvants Market - Revenue and Forecast to 2030 (US$ Million)
  • 8.2 Hepatitis
    • 8.2.1 Overview
    • 8.2.2 Hepatitis: Human Vaccine Adjuvants Market - Revenue and Forecast to 2030 (US$ Million)
  • 8.3 Human papilloma virus (HPV)
    • 8.3.1 Overview
    • 8.3.2 Human papilloma virus (HPV): Human Vaccine Adjuvants Market - Revenue and Forecast to 2030 (US$ Million)
  • 8.4 Others
    • 8.4.1 Overview
    • 8.4.2 Others: Human Vaccine Adjuvants Market - Revenue and Forecast to 2030 (US$ Million)

9. Human Vaccine Adjuvants Market Analysis - by End User

  • 9.1 Pharmaceutical and Biotechnology Companies
    • 9.1.1 Overview
    • 9.1.2 Pharmaceutical and Biotechnology Companies: Human Vaccine Adjuvants Market - Revenue and Forecast to 2030 (US$ Million)
  • 9.2 CMOs and CROs
    • 9.2.1 Overview
    • 9.2.2 CMOs and CROs: Human Vaccine Adjuvants Market - Revenue and Forecast to 2030 (US$ Million)
  • 9.3 Others
    • 9.3.1 Overview
    • 9.3.2 Others: Human Vaccine Adjuvants Market - Revenue and Forecast to 2030 (US$ Million)

10. Human Vaccine Adjuvants Market - Geographical Analysis

  • 10.1 Overview
  • 10.2 North America
    • 10.2.1 North America Human Vaccine Adjuvants Market Overview
    • 10.2.2 North America: Human Vaccine Adjuvants Market - Revenue and Forecast to 2030 (US$ Million)
    • 10.2.3 North America: Human Vaccine Adjuvants Market Breakdown, by Type
      • 10.2.3.1 North America: Human Vaccine Adjuvants Market - Revenue and Forecast Analysis - by Type
    • 10.2.4 North America: Human Vaccine Adjuvants Market Breakdown, by Application
      • 10.2.4.1 North America: Human Vaccine Adjuvants Market - Revenue and Forecast Analysis - by Application
    • 10.2.5 North America: Human Vaccine Adjuvants Market Breakdown, by End User
      • 10.2.5.1 North America: Human Vaccine Adjuvants Market - Revenue and Forecast Analysis - by End User
    • 10.2.6 North America: Human Vaccine Adjuvants Market - Revenue and Forecast Analysis - by Country
      • 10.2.6.1 North America: Human Vaccine Adjuvants Market - Revenue and Forecast Analysis - by Country
      • 10.2.6.2 United States: Human Vaccine Adjuvants Market - Revenue and Forecast to 2030 (US$ Million)
        • 10.2.6.2.1 United States: Human Vaccine Adjuvants Market Breakdown, by Type
        • 10.2.6.2.2 United States: Human Vaccine Adjuvants Market Breakdown, by Application
        • 10.2.6.2.3 United States: Human Vaccine Adjuvants Market Breakdown, by End User
      • 10.2.6.3 Canada: Human Vaccine Adjuvants Market - Revenue and Forecast to 2030 (US$ Million)
        • 10.2.6.3.1 Canada: Human Vaccine Adjuvants Market Breakdown, by Type
        • 10.2.6.3.2 Canada: Human Vaccine Adjuvants Market Breakdown, by Application
        • 10.2.6.3.3 Canada: Human Vaccine Adjuvants Market Breakdown, by End User
      • 10.2.6.4 Mexico: Human Vaccine Adjuvants Market - Revenue and Forecast to 2030 (US$ Million)
        • 10.2.6.4.1 Mexico: Human Vaccine Adjuvants Market Breakdown, by Type
        • 10.2.6.4.2 Mexico: Human Vaccine Adjuvants Market Breakdown, by Application
        • 10.2.6.4.3 Mexico: Human Vaccine Adjuvants Market Breakdown, by End User
  • 10.3 Europe
    • 10.3.1 Europe Human Vaccine Adjuvants Market Overview
    • 10.3.2 Europe: Human Vaccine Adjuvants Market - Revenue and Forecast to 2030 (US$ Million)
    • 10.3.3 Europe: Human Vaccine Adjuvants Market Breakdown, by Type
      • 10.3.3.1 Europe: Human Vaccine Adjuvants Market - Revenue and Forecast Analysis - by Type
    • 10.3.4 Europe: Human Vaccine Adjuvants Market Breakdown, by Application
      • 10.3.4.1 Europe: Human Vaccine Adjuvants Market - Revenue and Forecast Analysis - by Application
    • 10.3.5 Europe: Human Vaccine Adjuvants Market Breakdown, by End User
      • 10.3.5.1 Europe: Human Vaccine Adjuvants Market - Revenue and Forecast Analysis - by End User
    • 10.3.6 Europe: Human Vaccine Adjuvants Market - Revenue and Forecast Analysis - by Country
      • 10.3.6.1 Europe: Human Vaccine Adjuvants Market - Revenue and Forecast Analysis - by Country
      • 10.3.6.2 Germany: Human Vaccine Adjuvants Market - Revenue and Forecast to 2030 (US$ Million)
        • 10.3.6.2.1 Germany: Human Vaccine Adjuvants Market Breakdown, by Type
        • 10.3.6.2.2 Germany: Human Vaccine Adjuvants Market Breakdown, by Application
        • 10.3.6.2.3 Germany: Human Vaccine Adjuvants Market Breakdown, by End User
      • 10.3.6.3 United Kingdom: Human Vaccine Adjuvants Market - Revenue and Forecast to 2030 (US$ Million)
        • 10.3.6.3.1 United Kingdom: Human Vaccine Adjuvants Market Breakdown, by Type
        • 10.3.6.3.2 United Kingdom: Human Vaccine Adjuvants Market Breakdown, by Application
        • 10.3.6.3.3 United Kingdom: Human Vaccine Adjuvants Market Breakdown, by End User
      • 10.3.6.4 France: Human Vaccine Adjuvants Market - Revenue and Forecast to 2030 (US$ Million)
        • 10.3.6.4.1 France: Human Vaccine Adjuvants Market Breakdown, by Type
        • 10.3.6.4.2 France: Human Vaccine Adjuvants Market Breakdown, by Application
        • 10.3.6.4.3 France: Human Vaccine Adjuvants Market Breakdown, by End User
      • 10.3.6.5 Italy: Human Vaccine Adjuvants Market - Revenue and Forecast to 2030 (US$ Million)
        • 10.3.6.5.1 Italy: Human Vaccine Adjuvants Market Breakdown, by Type
        • 10.3.6.5.2 Italy: Human Vaccine Adjuvants Market Breakdown, by Application
        • 10.3.6.5.3 Italy: Human Vaccine Adjuvants Market Breakdown, by End User
      • 10.3.6.6 Spain: Human Vaccine Adjuvants Market - Revenue and Forecast to 2030 (US$ Million)
        • 10.3.6.6.1 Spain: Human Vaccine Adjuvants Market Breakdown, by Type
        • 10.3.6.6.2 Spain: Human Vaccine Adjuvants Market Breakdown, by Application
        • 10.3.6.6.3 Spain: Human Vaccine Adjuvants Market Breakdown, by End User
      • 10.3.6.7 Rest of Europe: Human Vaccine Adjuvants Market - Revenue and Forecast to 2030 (US$ Million)
        • 10.3.6.7.1 Rest of Europe: Human Vaccine Adjuvants Market Breakdown, by Type
        • 10.3.6.7.2 Rest of Europe: Human Vaccine Adjuvants Market Breakdown, by Application
        • 10.3.6.7.3 Rest of Europe: Human Vaccine Adjuvants Market Breakdown, by End User
  • 10.4 Asia Pacific
    • 10.4.1 Asia Pacific Human Vaccine Adjuvants Market Overview
    • 10.4.2 Asia Pacific: Human Vaccine Adjuvants Market - Revenue and Forecast to 2030 (US$ Million)
    • 10.4.3 Asia Pacific: Human Vaccine Adjuvants Market Breakdown, by Type
      • 10.4.3.1 Asia Pacific: Human Vaccine Adjuvants Market - Revenue and Forecast Analysis - by Type
    • 10.4.4 Asia Pacific: Human Vaccine Adjuvants Market Breakdown, by Application
      • 10.4.4.1 Asia Pacific: Human Vaccine Adjuvants Market - Revenue and Forecast Analysis - by Application
    • 10.4.5 Asia Pacific: Human Vaccine Adjuvants Market Breakdown, by End User
      • 10.4.5.1 Asia Pacific: Human Vaccine Adjuvants Market - Revenue and Forecast Analysis - by End User
    • 10.4.6 Asia Pacific: Human Vaccine Adjuvants Market - Revenue and Forecast Analysis - by Country
      • 10.4.6.1 Asia Pacific: Human Vaccine Adjuvants Market - Revenue and Forecast Analysis - by Country
      • 10.4.6.2 China: Human Vaccine Adjuvants Market - Revenue and Forecast to 2030 (US$ Million)
        • 10.4.6.2.1 China: Human Vaccine Adjuvants Market Breakdown, by Type
        • 10.4.6.2.2 China: Human Vaccine Adjuvants Market Breakdown, by Application
        • 10.4.6.2.3 China: Human Vaccine Adjuvants Market Breakdown, by End User
      • 10.4.6.3 Japan: Human Vaccine Adjuvants Market - Revenue and Forecast to 2030 (US$ Million)
        • 10.4.6.3.1 Japan: Human Vaccine Adjuvants Market Breakdown, by Type
        • 10.4.6.3.2 Japan: Human Vaccine Adjuvants Market Breakdown, by Application
        • 10.4.6.3.3 Japan: Human Vaccine Adjuvants Market Breakdown, by End User
      • 10.4.6.4 India: Human Vaccine Adjuvants Market - Revenue and Forecast to 2030 (US$ Million)
        • 10.4.6.4.1 India: Human Vaccine Adjuvants Market Breakdown, by Type
        • 10.4.6.4.2 India: Human Vaccine Adjuvants Market Breakdown, by Application
        • 10.4.6.4.3 India: Human Vaccine Adjuvants Market Breakdown, by End User
      • 10.4.6.5 Australia: Human Vaccine Adjuvants Market - Revenue and Forecast to 2030 (US$ Million)
        • 10.4.6.5.1 Australia: Human Vaccine Adjuvants Market Breakdown, by Type
        • 10.4.6.5.2 Australia: Human Vaccine Adjuvants Market Breakdown, by Application
        • 10.4.6.5.3 Australia: Human Vaccine Adjuvants Market Breakdown, by End User
      • 10.4.6.6 South Korea: Human Vaccine Adjuvants Market - Revenue and Forecast to 2030 (US$ Million)
        • 10.4.6.6.1 South Korea: Human Vaccine Adjuvants Market Breakdown, by Type
        • 10.4.6.6.2 South Korea: Human Vaccine Adjuvants Market Breakdown, by Application
        • 10.4.6.6.3 South Korea: Human Vaccine Adjuvants Market Breakdown, by End User
      • 10.4.6.7 Rest of APAC: Human Vaccine Adjuvants Market - Revenue and Forecast to 2030 (US$ Million)
        • 10.4.6.7.1 Rest of APAC: Human Vaccine Adjuvants Market Breakdown, by Type
        • 10.4.6.7.2 Rest of APAC: Human Vaccine Adjuvants Market Breakdown, by Application
        • 10.4.6.7.3 Rest of APAC: Human Vaccine Adjuvants Market Breakdown, by End User
  • 10.5 Middle East and Africa
    • 10.5.1 Middle East and Africa Human Vaccine Adjuvants Market Overview
    • 10.5.2 Middle East and Africa: Human Vaccine Adjuvants Market - Revenue and Forecast to 2030 (US$ Million)
    • 10.5.3 Middle East and Africa: Human Vaccine Adjuvants Market Breakdown, by Type
      • 10.5.3.1 Middle East and Africa: Human Vaccine Adjuvants Market - Revenue and Forecast Analysis - by Type
    • 10.5.4 Middle East and Africa: Human Vaccine Adjuvants Market Breakdown, by Application
      • 10.5.4.1 Middle East and Africa: Human Vaccine Adjuvants Market - Revenue and Forecast Analysis - by Application
    • 10.5.5 Middle East and Africa: Human Vaccine Adjuvants Market Breakdown, by End User
      • 10.5.5.1 Middle East and Africa: Human Vaccine Adjuvants Market - Revenue and Forecast Analysis - by End User
    • 10.5.6 Middle East and Africa: Human Vaccine Adjuvants Market - Revenue and Forecast Analysis - by Country
      • 10.5.6.1 Middle East and Africa: Human Vaccine Adjuvants Market - Revenue and Forecast Analysis - by Country
      • 10.5.6.2 Saudi Arabia: Human Vaccine Adjuvants Market - Revenue and Forecast to 2030 (US$ Million)
        • 10.5.6.2.1 Saudi Arabia: Human Vaccine Adjuvants Market Breakdown, by Type
        • 10.5.6.2.2 Saudi Arabia: Human Vaccine Adjuvants Market Breakdown, by Application
        • 10.5.6.2.3 Saudi Arabia: Human Vaccine Adjuvants Market Breakdown, by End User
      • 10.5.6.3 South Africa: Human Vaccine Adjuvants Market - Revenue and Forecast to 2030 (US$ Million)
        • 10.5.6.3.1 South Africa: Human Vaccine Adjuvants Market Breakdown, by Type
        • 10.5.6.3.2 South Africa: Human Vaccine Adjuvants Market Breakdown, by Application
        • 10.5.6.3.3 South Africa: Human Vaccine Adjuvants Market Breakdown, by End User
      • 10.5.6.4 United Arab Emirates: Human Vaccine Adjuvants Market - Revenue and Forecast to 2030 (US$ Million)
        • 10.5.6.4.1 United Arab Emirates: Human Vaccine Adjuvants Market Breakdown, by Type
        • 10.5.6.4.2 United Arab Emirates: Human Vaccine Adjuvants Market Breakdown, by Application
        • 10.5.6.4.3 United Arab Emirates: Human Vaccine Adjuvants Market Breakdown, by End User
      • 10.5.6.5 Rest of Middle East and Africa: Human Vaccine Adjuvants Market - Revenue and Forecast to 2030 (US$ Million)
        • 10.5.6.5.1 Rest of Middle East and Africa: Human Vaccine Adjuvants Market Breakdown, by Type
        • 10.5.6.5.2 Rest of Middle East and Africa: Human Vaccine Adjuvants Market Breakdown, by Application
        • 10.5.6.5.3 Rest of Middle East and Africa: Human Vaccine Adjuvants Market Breakdown, by End User
  • 10.6 South and Central America
    • 10.6.1 South and Central America Human Vaccine Adjuvants Market Overview
    • 10.6.2 South and Central America: Human Vaccine Adjuvants Market - Revenue and Forecast to 2030 | (US$ Million)
    • 10.6.3 South and Central America: Human Vaccine Adjuvants Market Breakdown, by Type
      • 10.6.3.1 South and Central America: Human Vaccine Adjuvants Market - Revenue and Forecast Analysis - by Type
    • 10.6.4 South and Central America: Human Vaccine Adjuvants Market Breakdown, by Application
      • 10.6.4.1 South and Central America: Human Vaccine Adjuvants Market - Revenue and Forecast Analysis - by Application
    • 10.6.5 South and Central America: Human Vaccine Adjuvants Market Breakdown, by End User
      • 10.6.5.1 South and Central America: Human Vaccine Adjuvants Market - Revenue and Forecast Analysis - by End User
    • 10.6.6 South and Central America: Human Vaccine Adjuvants Market - Revenue and Forecast Analysis - by Country
      • 10.6.6.1 South and Central America: Human Vaccine Adjuvants Market - Revenue and Forecast Analysis - by Country
      • 10.6.6.2 Brazil: Human Vaccine Adjuvants Market - Revenue and Forecast to 2030 (US$ Million)
        • 10.6.6.2.1 Brazil: Human Vaccine Adjuvants Market Breakdown, by Type
        • 10.6.6.2.2 Brazil: Human Vaccine Adjuvants Market Breakdown, by Application
        • 10.6.6.2.3 Brazil: Human Vaccine Adjuvants Market Breakdown, by End User
      • 10.6.6.3 Argentina: Human Vaccine Adjuvants Market - Revenue and Forecast to 2030 (US$ Million)
        • 10.6.6.3.1 Argentina: Human Vaccine Adjuvants Market Breakdown, by Type
        • 10.6.6.3.2 Argentina: Human Vaccine Adjuvants Market Breakdown, by Application
        • 10.6.6.3.3 Argentina: Human Vaccine Adjuvants Market Breakdown, by End User
      • 10.6.6.4 Rest of South and Central America: Human Vaccine Adjuvants Market - Revenue and Forecast to 2030 (US$ Million)
        • 10.6.6.4.1 Rest of South and Central America: Human Vaccine Adjuvants Market Breakdown, by Type
        • 10.6.6.4.2 Rest of South and Central America: Human Vaccine Adjuvants Market Breakdown, by Application
        • 10.6.6.4.3 Rest of South and Central America: Human Vaccine Adjuvants Market Breakdown, by End User

11. Industry Landscape

  • 11.1 Overview

12. Company Profiles

  • 12.1 Novartis AG
    • 12.1.1 Key Facts
    • 12.1.2 Business Description
    • 12.1.3 Products and Services
    • 12.1.4 Financial Overview
    • 12.1.5 SWOT Analysis
    • 12.1.6 Key Developments
  • 12.2 Dynavax Technologies Corp
    • 12.2.1 Key Facts
    • 12.2.2 Business Description
    • 12.2.3 Products and Services
    • 12.2.4 Financial Overview
    • 12.2.5 SWOT Analysis
    • 12.2.6 Key Developments
  • 12.3 CSL Ltd
    • 12.3.1 Key Facts
    • 12.3.2 Business Description
    • 12.3.3 Products and Services
    • 12.3.4 Financial Overview
    • 12.3.5 SWOT Analysis
    • 12.3.6 Key Developments
  • 12.4 Seppic SA
    • 12.4.1 Key Facts
    • 12.4.2 Business Description
    • 12.4.3 Products and Services
    • 12.4.4 Financial Overview
    • 12.4.5 SWOT Analysis
    • 12.4.6 Key Developments
  • 12.5 SPI Pharma Inc
    • 12.5.1 Key Facts
    • 12.5.2 Business Description
    • 12.5.3 Products and Services
    • 12.5.4 Financial Overview
    • 12.5.5 SWOT Analysis
    • 12.5.6 Key Developments
  • 12.6 Hawaii Biotech Inc
    • 12.6.1 Key Facts
    • 12.6.2 Business Description
    • 12.6.3 Products and Services
    • 12.6.4 Financial Overview
    • 12.6.5 SWOT Analysis
    • 12.6.6 Key Developments
  • 12.7 Croda International Plc
    • 12.7.1 Key Facts
    • 12.7.2 Business Description
    • 12.7.3 Products and Services
    • 12.7.4 Financial Overview
    • 12.7.5 SWOT Analysis
    • 12.7.6 Key Developments
  • 12.8 Novavax Inc
    • 12.8.1 Key Facts
    • 12.8.2 Business Description
    • 12.8.3 Products and Services
    • 12.8.4 Financial Overview
    • 12.8.5 SWOT Analysis
    • 12.8.6 Key Developments
  • 12.9 Phibro Animal Health Corp
    • 12.9.1 Key Facts
    • 12.9.2 Business Description
    • 12.9.3 Products and Services
    • 12.9.4 Financial Overview
    • 12.9.5 SWOT Analysis
    • 12.9.6 Key Developments
  • 12.10 Creative Biolabs Inc
    • 12.10.1 Key Facts
    • 12.10.2 Business Description
    • 12.10.3 Products and Services
    • 12.10.4 Financial Overview
    • 12.10.5 SWOT Analysis
    • 12.10.6 Key Developments

13. Appendix

  • 13.1 About The Insight Partners
  • 13.2 Glossary of Terms

List Of Tables

  • Table 1. Human Vaccine Adjuvants Market Segmentation
  • Table 2. Human Vaccine Adjuvants Market - Revenue and Forecast to 2030 (US$ Million)
  • Table 3. Human Vaccine Adjuvants Market - Revenue and Forecast to 2030 (US$ Million) - by Type
  • Table 4. Human Vaccine Adjuvants Market - Revenue and Forecast to 2030 (US$ Million) - by Application
  • Table 5. Human Vaccine Adjuvants Market - Revenue and Forecast to 2030 (US$ Million) - by End User
  • Table 6. North America: Human Vaccine Adjuvants Market - Revenue and Forecast to 2030(US$ Million) - by Type
  • Table 7. North America: Human Vaccine Adjuvants Market - Revenue and Forecast to 2030(US$ Million) - by Application
  • Table 8. North America: Human Vaccine Adjuvants Market - Revenue and Forecast to 2030(US$ Million) - by End User
  • Table 9. North America: Human Vaccine Adjuvants Market - Revenue and Forecast to 2030(US$ Million) - by Country
  • Table 10. United States: Human Vaccine Adjuvants Market - Revenue and Forecast to 2030(US$ Million) - by Type
  • Table 11. United States: Human Vaccine Adjuvants Market - Revenue and Forecast to 2030(US$ Million) - by Application
  • Table 12. United States: Human Vaccine Adjuvants Market - Revenue and Forecast to 2030(US$ Million) - by End User
  • Table 13. Canada: Human Vaccine Adjuvants Market - Revenue and Forecast to 2030(US$ Million) - by Type
  • Table 14. Canada: Human Vaccine Adjuvants Market - Revenue and Forecast to 2030(US$ Million) - by Application
  • Table 15. Canada: Human Vaccine Adjuvants Market - Revenue and Forecast to 2030(US$ Million) - by End User
  • Table 16. Mexico: Human Vaccine Adjuvants Market - Revenue and Forecast to 2030(US$ Million) - by Type
  • Table 17. Mexico: Human Vaccine Adjuvants Market - Revenue and Forecast to 2030(US$ Million) - by Application
  • Table 18. Mexico: Human Vaccine Adjuvants Market - Revenue and Forecast to 2030(US$ Million) - by End User
  • Table 19. Europe: Human Vaccine Adjuvants Market - Revenue and Forecast to 2030(US$ Million) - by Type
  • Table 20. Europe: Human Vaccine Adjuvants Market - Revenue and Forecast to 2030(US$ Million) - by Application
  • Table 21. Europe: Human Vaccine Adjuvants Market - Revenue and Forecast to 2030(US$ Million) - by End User
  • Table 22. Europe: Human Vaccine Adjuvants Market - Revenue and Forecast to 2030(US$ Million) - by Country
  • Table 23. Germany: Human Vaccine Adjuvants Market - Revenue and Forecast to 2030(US$ Million) - by Type
  • Table 24. Germany: Human Vaccine Adjuvants Market - Revenue and Forecast to 2030(US$ Million) - by Application
  • Table 25. Germany: Human Vaccine Adjuvants Market - Revenue and Forecast to 2030(US$ Million) - by End User
  • Table 26. United Kingdom: Human Vaccine Adjuvants Market - Revenue and Forecast to 2030(US$ Million) - by Type
  • Table 27. United Kingdom: Human Vaccine Adjuvants Market - Revenue and Forecast to 2030(US$ Million) - by Application
  • Table 28. United Kingdom: Human Vaccine Adjuvants Market - Revenue and Forecast to 2030(US$ Million) - by End User
  • Table 29. France: Human Vaccine Adjuvants Market - Revenue and Forecast to 2030(US$ Million) - by Type
  • Table 30. France: Human Vaccine Adjuvants Market - Revenue and Forecast to 2030(US$ Million) - by Application
  • Table 31. France: Human Vaccine Adjuvants Market - Revenue and Forecast to 2030(US$ Million) - by End User
  • Table 32. Italy: Human Vaccine Adjuvants Market - Revenue and Forecast to 2030(US$ Million) - by Type
  • Table 33. Italy: Human Vaccine Adjuvants Market - Revenue and Forecast to 2030(US$ Million) - by Application
  • Table 34. Italy: Human Vaccine Adjuvants Market - Revenue and Forecast to 2030(US$ Million) - by End User
  • Table 35. Spain: Human Vaccine Adjuvants Market - Revenue and Forecast to 2030(US$ Million) - by Type
  • Table 36. Spain: Human Vaccine Adjuvants Market - Revenue and Forecast to 2030(US$ Million) - by Application
  • Table 37. Spain: Human Vaccine Adjuvants Market - Revenue and Forecast to 2030(US$ Million) - by End User
  • Table 38. Rest of Europe: Human Vaccine Adjuvants Market - Revenue and Forecast to 2030(US$ Million) - by Type
  • Table 39. Rest of Europe: Human Vaccine Adjuvants Market - Revenue and Forecast to 2030(US$ Million) - by Application
  • Table 40. Rest of Europe: Human Vaccine Adjuvants Market - Revenue and Forecast to 2030(US$ Million) - by End User
  • Table 41. Asia Pacific: Human Vaccine Adjuvants Market - Revenue and Forecast to 2030(US$ Million) - by Type
  • Table 42. Asia Pacific: Human Vaccine Adjuvants Market - Revenue and Forecast to 2030(US$ Million) - by Application
  • Table 43. Asia Pacific: Human Vaccine Adjuvants Market - Revenue and Forecast to 2030(US$ Million) - by End User
  • Table 44. Asia Pacific: Human Vaccine Adjuvants Market - Revenue and Forecast to 2030(US$ Million) - by Country
  • Table 45. China: Human Vaccine Adjuvants Market - Revenue and Forecast to 2030(US$ Million) - by Type
  • Table 46. China: Human Vaccine Adjuvants Market - Revenue and Forecast to 2030(US$ Million) - by Application
  • Table 47. China: Human Vaccine Adjuvants Market - Revenue and Forecast to 2030(US$ Million) - by End User
  • Table 48. Japan: Human Vaccine Adjuvants Market - Revenue and Forecast to 2030(US$ Million) - by Type
  • Table 49. Japan: Human Vaccine Adjuvants Market - Revenue and Forecast to 2030(US$ Million) - by Application
  • Table 50. Japan: Human Vaccine Adjuvants Market - Revenue and Forecast to 2030(US$ Million) - by End User
  • Table 51. India: Human Vaccine Adjuvants Market - Revenue and Forecast to 2030(US$ Million) - by Type
  • Table 52. India: Human Vaccine Adjuvants Market - Revenue and Forecast to 2030(US$ Million) - by Application
  • Table 53. India: Human Vaccine Adjuvants Market - Revenue and Forecast to 2030(US$ Million) - by End User
  • Table 54. Australia: Human Vaccine Adjuvants Market - Revenue and Forecast to 2030(US$ Million) - by Type
  • Table 55. Australia: Human Vaccine Adjuvants Market - Revenue and Forecast to 2030(US$ Million) - by Application
  • Table 56. Australia: Human Vaccine Adjuvants Market - Revenue and Forecast to 2030(US$ Million) - by End User
  • Table 57. South Korea: Human Vaccine Adjuvants Market - Revenue and Forecast to 2030(US$ Million) - by Type
  • Table 58. South Korea: Human Vaccine Adjuvants Market - Revenue and Forecast to 2030(US$ Million) - by Application
  • Table 59. South Korea: Human Vaccine Adjuvants Market - Revenue and Forecast to 2030(US$ Million) - by End User
  • Table 60. Rest of APAC: Human Vaccine Adjuvants Market - Revenue and Forecast to 2030(US$ Million) - by Type
  • Table 61. Rest of APAC: Human Vaccine Adjuvants Market - Revenue and Forecast to 2030(US$ Million) - by Application
  • Table 62. Rest of APAC: Human Vaccine Adjuvants Market - Revenue and Forecast to 2030(US$ Million) - by End User
  • Table 63. Middle East and Africa: Human Vaccine Adjuvants Market - Revenue and Forecast to 2030(US$ Million) - by Type
  • Table 64. Middle East and Africa: Human Vaccine Adjuvants Market - Revenue and Forecast to 2030(US$ Million) - by Application
  • Table 65. Middle East and Africa: Human Vaccine Adjuvants Market - Revenue and Forecast to 2030(US$ Million) - by End User
  • Table 66. Middle East and Africa: Human Vaccine Adjuvants Market - Revenue and Forecast to 2030(US$ Million) - by Country
  • Table 67. Saudi Arabia: Human Vaccine Adjuvants Market - Revenue and Forecast to 2030(US$ Million) - by Type
  • Table 68. Saudi Arabia: Human Vaccine Adjuvants Market - Revenue and Forecast to 2030(US$ Million) - by Application
  • Table 69. Saudi Arabia: Human Vaccine Adjuvants Market - Revenue and Forecast to 2030(US$ Million) - by End User
  • Table 70. South Africa: Human Vaccine Adjuvants Market - Revenue and Forecast to 2030(US$ Million) - by Type
  • Table 71. South Africa: Human Vaccine Adjuvants Market - Revenue and Forecast to 2030(US$ Million) - by Application
  • Table 72. South Africa: Human Vaccine Adjuvants Market - Revenue and Forecast to 2030(US$ Million) - by End User
  • Table 73. United Arab Emirates: Human Vaccine Adjuvants Market - Revenue and Forecast to 2030(US$ Million) - by Type
  • Table 74. United Arab Emirates: Human Vaccine Adjuvants Market - Revenue and Forecast to 2030(US$ Million) - by Application
  • Table 75. United Arab Emirates: Human Vaccine Adjuvants Market - Revenue and Forecast to 2030(US$ Million) - by End User
  • Table 76. Rest of Middle East and Africa: Human Vaccine Adjuvants Market - Revenue and Forecast to 2030(US$ Million) - by Type
  • Table 77. Rest of Middle East and Africa: Human Vaccine Adjuvants Market - Revenue and Forecast to 2030(US$ Million) - by Application
  • Table 78. Rest of Middle East and Africa: Human Vaccine Adjuvants Market - Revenue and Forecast to 2030(US$ Million) - by End User
  • Table 79. South and Central America: Human Vaccine Adjuvants Market - Revenue and Forecast to 2030(US$ Million) - by Type
  • Table 80. South and Central America: Human Vaccine Adjuvants Market - Revenue and Forecast to 2030(US$ Million) - by Application
  • Table 81. South and Central America: Human Vaccine Adjuvants Market - Revenue and Forecast to 2030(US$ Million) - by End User
  • Table 82. South and Central America: Human Vaccine Adjuvants Market - Revenue and Forecast to 2030(US$ Million) - by Country
  • Table 83. Brazil: Human Vaccine Adjuvants Market - Revenue and Forecast to 2030(US$ Million) - by Type
  • Table 84. Brazil: Human Vaccine Adjuvants Market - Revenue and Forecast to 2030(US$ Million) - by Application
  • Table 85. Brazil: Human Vaccine Adjuvants Market - Revenue and Forecast to 2030(US$ Million) - by End User
  • Table 86. Argentina: Human Vaccine Adjuvants Market - Revenue and Forecast to 2030(US$ Million) - by Type
  • Table 87. Argentina: Human Vaccine Adjuvants Market - Revenue and Forecast to 2030(US$ Million) - by Application
  • Table 88. Argentina: Human Vaccine Adjuvants Market - Revenue and Forecast to 2030(US$ Million) - by End User
  • Table 89. Rest of South and Central America: Human Vaccine Adjuvants Market - Revenue and Forecast to 2030 (US$ Million) - by Type
  • Table 90. Rest of South and Central America: Human Vaccine Adjuvants Market - Revenue and Forecast to 2030(US$ Million) - by Application
  • Table 91. Rest of South and Central America: Human Vaccine Adjuvants Market - Revenue and Forecast to 2030 (US$ Million) - by End User
  • Table 92. Recent Growth Strategies in the Human Vaccine Adjuvants Market
  • Table 93. Glossary of Terms, Global Human Vaccine Adjuvants Market

List Of Figures

  • Figure 1. Human Vaccine Adjuvants Market Segmentation, by Geography
  • Figure 2. PEST Analysis
  • Figure 3. Impact Analysis of Drivers and Restraints
  • Figure 4. Human Vaccine Adjuvants Market Breakdown by Geography, 2022 and 2030 (%)
  • Figure 5. Human Vaccine Adjuvants Market Revenue (US$ Million), 2022 - 2030
  • Figure 6. Human Vaccine Adjuvants Market Share (%) - by Type (2022 and 2030)
  • Figure 7. Particulate Adjuvant: Human Vaccine Adjuvants Market - Revenue and Forecast to 2030 (US$ Million)
  • Figure 8. Emulsion Adjuvant: Human Vaccine Adjuvants Market - Revenue and Forecast to 2030 (US$ Million)
  • Figure 9. Combination Adjuvant: Human Vaccine Adjuvants Market - Revenue and Forecast to 2030 (US$ Million)
  • Figure 10. Others: Human Vaccine Adjuvants Market - Revenue and Forecast to 2030 (US$ Million)
  • Figure 11. Human Vaccine Adjuvants Market Share (%) - by Application (2022 and 2030)
  • Figure 12. Influenza: Human Vaccine Adjuvants Market - Revenue and Forecast to 2030 (US$ Million)
  • Figure 13. Hepatitis: Human Vaccine Adjuvants Market - Revenue and Forecast to 2030 (US$ Million)
  • Figure 14. Human papilloma virus (HPV): Human Vaccine Adjuvants Market - Revenue and Forecast to 2030 (US$ Million)
  • Figure 15. Others: Human Vaccine Adjuvants Market - Revenue and Forecast to 2030 (US$ Million)
  • Figure 16. Human Vaccine Adjuvants Market Share (%) - by End User (2022 and 2030)
  • Figure 17. Pharmaceutical and Biotechnology Companies: Human Vaccine Adjuvants Market - Revenue and Forecast to 2030 (US$ Million)
  • Figure 18. CMOs and CROs: Human Vaccine Adjuvants Market - Revenue and Forecast to 2030 (US$ Million)
  • Figure 19. Others: Human Vaccine Adjuvants Market - Revenue and Forecast to 2030 (US$ Million)
  • Figure 20. Human Vaccine Adjuvants Market Breakdown by Region, 2022 and 2030 (%)
  • Figure 21. North America: Human Vaccine Adjuvants Market - Revenue and Forecast to 2030(US$ Million)
  • Figure 22. North America: Human Vaccine Adjuvants Market Breakdown, by Type (2022 and 2030)
  • Figure 23. North America: Human Vaccine Adjuvants Market Breakdown, by Application (2022 and 2030)
  • Figure 24. North America: Human Vaccine Adjuvants Market Breakdown, by End User (2022 and 2030)
  • Figure 25. North America: Human Vaccine Adjuvants Market Breakdown, by Key Countries, 2022 and 2030 (%)
  • Figure 26. United States: Human Vaccine Adjuvants Market - Revenue and Forecast to 2030(US$ Million)
  • Figure 27. Canada: Human Vaccine Adjuvants Market - Revenue and Forecast to 2030(US$ Million)
  • Figure 28. Mexico: Human Vaccine Adjuvants Market - Revenue and Forecast to 2030(US$ Million)
  • Figure 29. Europe: Human Vaccine Adjuvants Market - Revenue and Forecast to 2030(US$ Million)
  • Figure 30. Europe: Human Vaccine Adjuvants Market Breakdown, by Type (2022 and 2030)
  • Figure 31. Europe: Human Vaccine Adjuvants Market Breakdown, by Application (2022 and 2030)
  • Figure 32. Europe: Human Vaccine Adjuvants Market Breakdown, by End User (2022 and 2030)
  • Figure 33. Europe: Human Vaccine Adjuvants Market Breakdown, by Key Countries, 2022 and 2030 (%)
  • Figure 34. Germany: Human Vaccine Adjuvants Market - Revenue and Forecast to 2030(US$ Million)
  • Figure 35. United Kingdom: Human Vaccine Adjuvants Market - Revenue and Forecast to 2030(US$ Million)
  • Figure 36. France: Human Vaccine Adjuvants Market - Revenue and Forecast to 2030(US$ Million)
  • Figure 37. Italy: Human Vaccine Adjuvants Market - Revenue and Forecast to 2030(US$ Million)
  • Figure 38. Spain: Human Vaccine Adjuvants Market - Revenue and Forecast to 2030(US$ Million)
  • Figure 39. Rest of Europe: Human Vaccine Adjuvants Market - Revenue and Forecast to 2030(US$ Million)
  • Figure 40. Asia Pacific: Human Vaccine Adjuvants Market - Revenue and Forecast to 2030(US$ Million)
  • Figure 41. Asia Pacific: Human Vaccine Adjuvants Market Breakdown, by Type (2022 and 2030)
  • Figure 42. Asia Pacific: Human Vaccine Adjuvants Market Breakdown, by Application (2022 and 2030)
  • Figure 43. Asia Pacific: Human Vaccine Adjuvants Market Breakdown, by End User (2022 and 2030)
  • Figure 44. Asia Pacific: Human Vaccine Adjuvants Market Breakdown, by Key Countries, 2022 and 2030 (%)
  • Figure 45. China: Human Vaccine Adjuvants Market - Revenue and Forecast to 2030(US$ Million)
  • Figure 46. Japan: Human Vaccine Adjuvants Market - Revenue and Forecast to 2030(US$ Million)
  • Figure 47. India: Human Vaccine Adjuvants Market - Revenue and Forecast to 2030(US$ Million)
  • Figure 48. Australia: Human Vaccine Adjuvants Market - Revenue and Forecast to 2030(US$ Million)
  • Figure 49. South Korea: Human Vaccine Adjuvants Market - Revenue and Forecast to 2030(US$ Million)
  • Figure 50. Rest of APAC: Human Vaccine Adjuvants Market - Revenue and Forecast to 2030(US$ Million)
  • Figure 51. Middle East and Africa: Human Vaccine Adjuvants Market - Revenue and Forecast to 2030(US$ Million)
  • Figure 52. Middle East and Africa: Human Vaccine Adjuvants Market Breakdown, by Type (2022 and 2030)
  • Figure 53. Middle East and Africa: Human Vaccine Adjuvants Market Breakdown, by Application (2022 and 2030)
  • Figure 54. Middle East and Africa: Human Vaccine Adjuvants Market Breakdown, by End User (2022 and 2030)
  • Figure 55. Middle East and Africa: Human Vaccine Adjuvants Market Breakdown, by Key Countries, 2022 and 2030 (%)
  • Figure 56. Saudi Arabia: Human Vaccine Adjuvants Market - Revenue and Forecast to 2030(US$ Million)
  • Figure 57. South Africa: Human Vaccine Adjuvants Market - Revenue and Forecast to 2030(US$ Million)
  • Figure 58. United Arab Emirates: Human Vaccine Adjuvants Market - Revenue and Forecast to 2030(US$ Million)
  • Figure 59. Rest of Middle East and Africa: Human Vaccine Adjuvants Market - Revenue and Forecast to 2030(US$ Million)
  • Figure 60. South and Central America: Human Vaccine Adjuvants Market - Revenue and Forecast to 2030(US$ Million)
  • Figure 61. South and Central America: Human Vaccine Adjuvants Market Breakdown, by Type (2022 and 2030)
  • Figure 62. South and Central America: Human Vaccine Adjuvants Market Breakdown, by Application (2022 and 2030)
  • Figure 63. South and Central America: Human Vaccine Adjuvants Market Breakdown, by End User (2022 and 2030)
  • Figure 64. South and Central America: Human Vaccine Adjuvants Market Breakdown, by Key Countries, 2022 and 2030 (%)
  • Figure 65. Brazil: Human Vaccine Adjuvants Market - Revenue and Forecast to 2030(US$ Million)
  • Figure 66. Argentina: Human Vaccine Adjuvants Market - Revenue and Forecast to 2030(US$ Million)
  • Figure 67. Rest of South and Central America: Human Vaccine Adjuvants Market - Revenue and Forecast to 2030(US$ Million)